Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Methods Mol Biol ; 2406: 339-358, 2022.
Article in English | MEDLINE | ID: mdl-35089567

ABSTRACT

In the last two decades, numerous innovative advances, strategies and protocols have been developed and optimized to improve the quality and quantity of soluble recombinant protein production in E. coli. One of the major challenges being the coelution of chaperone proteins along with desired recombinant protein of interest. The removal of chaperones is important for protein yield, structural determination, optimal activity, and desired function of the recombinant protein. In this chapter, we outline various strategies for removal of chaperone contaminants from oligomeric proteins, with the ultimate objective of ameliorating the quality and proper folding of recombinant proteins. We have discussed in detail the purification and expression of full-length protein, GNE (UDP-N-acetylglucosamine 2-epimerase/ N-acetylmannosamine kinase), as a case study for chaperone removal.


Subject(s)
Escherichia coli Proteins , Escherichia coli , Escherichia coli/metabolism , Escherichia coli Proteins/metabolism , Molecular Chaperones/genetics , Molecular Chaperones/metabolism , Recombinant Proteins/metabolism
2.
Integr Cancer Ther ; 19: 1534735420920711, 2020.
Article in English | MEDLINE | ID: mdl-32463309

ABSTRACT

Background:Rhazya stricta has been used as a folkloric medicinal herb for treating various diseases such as diabetes, inflammatory disorders, and sore throat. Several studies have revealed the potential of this plant as an important source of phytochemicals with anticancer properties. Objective: The present study was designed to isolate a novel anticancer compound from Rhazya stricta and elucidate its mechanism of action using genomics approach. Methods:Rhazya stricta leaves extract was prepared, and several alkaloids were purified and characterized. These alkaloids were screened for their anticancer potential. One of the alkaloids, termed as isopicrinine, showed efficient cytotoxicity against MCF7 breast cancer cell line and was selected for further analysis. RNA-Seq transcription profiling was conducted to identify the affected genes and cellular pathways in MCF7 cells after treatment with isopicrinine alkaloid. Results: In vitro studies revealed that newly identified isopicrinine alkaloid possess efficient anticancer activity. Exposure of MCF7 cells with isopicrinine affected the expression of various genes involved in p53 signaling pathway. One of the crucial proapoptotic genes, significantly upregulated in MCF7 after exposure to alkaloid, was PUMA (p53 upregulated modulator of apoptosis), which is involved in p53-dependent and -independent apoptosis. Moreover, exposure of sublethal dose of isopicrinine alkaloid in breast cancer cell line led to the downregulation of survivin, which is involved in negative regulation of apoptosis. Besides, several genes involved in mitosis and cell proliferation were significantly downregulated. Conclusion: In this article, we report the determination of a new alkaloid isopicrinine from the aerial parts of Rhazya stricta with anticancer property. This compound has the potential to be developed as a drug for curing cancer.


Subject(s)
Alkaloids , Apocynaceae , Gene Expression Profiling , Plants, Medicinal , Humans , Plant Extracts
3.
Biosci. j. (Online) ; 36(3): 1024-1031, 01-05-2020. tab, ilus
Article in English | LILACS | ID: biblio-1147195

ABSTRACT

Halophilic bacteria are microorganisms that grow optimally in the presence of the very high concentration of sodium chloride. Halophiles are vital sources of various enzymes including hydrolases, which are very stable and catalytically highly efficient at high salt concentration and other extreme conditions such as high temperature, pH and presence of organic solvents. Several hydrolases such as amylases, proteases, and lipases have been obtained from halophilic bacteria and are commonly used for various industrial applications. We initiated a screening to isolate and characterize the halophilic bacteria from the Red Sea, which is one of the saltiest bodies of water in the world. Water and soil samples, collected from the Red Sea coast, Jeddah, Saudi Arabia, were screened for isolation of halophilic bacteria. Ten bacterial isolates were obtained, which were characterized by biochemical tests and 16S rRNA gene sequencing. Hydrolase producing bacteria among the isolates were screened by plate assay on starch and gelatin agar plates for amylase and protease, respectively. Two bacterial isolates i.e. Bacillus glycinifermentans S3 and Enterobacter cloacae W1were found to possess significant amylase and protease activity.


Bactérias halofílicas são microrganismos que crescem de maneira ideal na presença de uma concentração muito alta de cloreto de sódio. Halófilos são fontes vitais de várias enzimas, incluindo hidrolases, que são muito estáveis e cataliticamente altamente eficientes em alta concentração de sal e outras condições extremas, como alta temperatura, pH e presença de solventes orgânicos. Várias hidrolases como amilases, proteases e lipases foram obtidas a partir de bactérias halofílicas e são comumente usadas para várias aplicações industriais. Iniciamos uma triagem para isolar e caracterizar as bactérias halofílicas do Mar Vermelho, que é um dos corpos de água mais salgados do mundo. Amostras de água e solo, coletadas na costa do Mar Vermelho, Jeddah, na Arábia Saudita, foram examinadas quanto ao isolamento de bactérias halofílicas. Foram obtidos dez isolados bacterianos, caracterizados por testes bioquímicos e seqüenciamento do gene 16S rRNA. As bactérias produtoras de hidrolase entre os isolados foram triadas por ensaio em placa em placas de amido e ágar de gelatina para amilase e protease, respectivamente. Verificou-se que dois isolados bacterianos, isto é, Bacillus glycinifermentans S3 e Enterobacter cloacae W1, possuíam significativa atividade de amilase e protease.


Subject(s)
Peptide Hydrolases , Halobacteriales , Salinity , Amylases , Hydrolases
4.
Chem Cent J ; 11: 11, 2017.
Article in English | MEDLINE | ID: mdl-28194226

ABSTRACT

Rhazya stricta is a unique medicinal plant source for many indole alkaloids, non-alkaloids, flavonoids, triterpenes and other unknown molecules with tremendous potential for therapeutic applications against many diseases. In the present article, we generated computational data on predictive properties and activity across two key therapeutic areas of cancer and obesity, and corresponding cheminformatics studies were carried out to examine druggable properties of these alkaloids. Computed physiochemical properties of the 78 indole alkaloids from R. stricta plant using industry-standard scientific molecular modeling software and their predictive anti-cancer activities from reliable web-source technologies indicate their plausible therapeutic applications. Their predictive ADME properties are further indicative of their drug-like-ness. We believe that the top-ranked molecules with anti-cancer activity are clearly amenable to chemical modifications for creating potent, safe and efficacious compounds with the feasibility of generating new chemical entities after pre-clinical and clinical studies.

5.
Mol Med Rep ; 6(1): 9-15, 2012 07.
Article in English | MEDLINE | ID: mdl-22576734

ABSTRACT

RNA interference (RNAi) is a sequence-specific, post-transcriptional gene silencing mechanism in animals and plants, which is mediated by double-stranded RNA (dsRNA). There has recently been an increasing interest in harnessing the gene silencing activity of dsRNA to develop novel drugs for the treatment of various diseases, such as cancer, neurological disorders, age-related macular degeneration and viral infections. Small interfering RNA (siRNA)-based drugs have distinct advantages over conventional small molecule or protein-based drugs, including high specificity, higher potency and reduced toxicity. However, there are several technical obstacles to overcome before siRNA-based drugs reach the clinic. Delivery of siRNA to the target tissues and stability in the serum remain a major challenge and are the main focus of current research and development efforts. This review focused primarily on the progress made in developing RNAi as therapeutics for cancer and the challenges associated with its clinical development. Use of ligands recognizing cell-specific receptors to achieve tumor-specific delivery of siRNA, methods for enhanced siRNA delivery, improving the bioavailability and pharmacokinetic properties of siRNA and reducing the off-target effects and non-specific gene silencing are discussed in the light of current evidence.


Subject(s)
Neoplasms/therapy , RNA Interference , RNA, Small Interfering/therapeutic use , Animals , Clinical Trials as Topic , Humans , Neoplasms/genetics , RNA, Small Interfering/adverse effects , RNA, Small Interfering/pharmacokinetics
6.
Biochem Biophys Res Commun ; 391(1): 739-43, 2010 Jan 01.
Article in English | MEDLINE | ID: mdl-19944070

ABSTRACT

SIRT1, human ortholog of yeast SIR2 protein, deacetylates histones and several other transcription factors. Recently, SIRT1 has emerged as a drug target for treating age related diseases, type II diabetes, neurodegeneration, inflammation and cancer. Here, we have optimized production of functionally active wild type full-length SIRT1 protein and its N-terminal deleted mutants. In a comparative study, we found that the region containing 192-208 amino acids towards the N-terminus is critical for right conformational folding of the protein to retain its deacetylase activity. The EC(50) and IC(50) values obtained with standard modulators showed that the SRT(748) & SRT(556) can deacetylate substrate and are activated by resveratrol, whereas, deacetylase activity of all the other deletion mutants (SRT(540), SRT(532), SRT(507) and SRT(503)) was lost. We further report that the peptide substrate K(m) for SRT(748) (70+/-5.2 microM) was comparable to SRT(556) (93+/-5.4 microM). The K(m) for NAD(+) substrate was 176 & 274 microM for SRT(748) and SRT(556), respectively. Similar substrate affinity studies demonstrate that either of the protein (SRT(748) or SRT(556)) can be utilized for screening SIRT1 modulators. We have also examined critical regions in SIRT1 required for deacetylase activity as well as kinetic analyses of SIRT1 proteins.


Subject(s)
Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Sirtuin 1/chemistry , Sirtuin 1/genetics , Escherichia coli/genetics , Escherichia coli/metabolism , Humans , Protein Conformation , Recombinant Proteins/biosynthesis , Resveratrol , Sequence Deletion , Sirtuin 1/biosynthesis , Stilbenes/pharmacology
7.
J Toxicol Sci ; 33(2): 163-73, 2008 May.
Article in English | MEDLINE | ID: mdl-18544908

ABSTRACT

Drug-induced hepatotoxicity is one of the most common adverse events associated with drug withdrawal from the market. Elucidating the molecular mechanism of hepatotoxicity is essential to predict the safety of a new molecule. To examine genes involved in hepatotoxicity, we have used oligonucleotide CodeLink Bioarrays and determined the transcriptional profile of mice liver treated with hepatotoxic drug N-acetyl-p-amino-phenol (APAP) as well as its non-toxic analog N-acetyl-m-amino-phenol (AMAP). Out of 20,000 genes analyzed, 896 showed differential expression of > or = 2-fold (648 upregulated and 248 downregulated) within the liver of APAP treated mice as compared to control. In comparison to AMAP treated mice, 62 genes were upregulated and 70 genes were downregulated in mice liver after APAP treatment. Functional classification of these differentially expressed genes identified genes associated with stress response, cell cycle, growth inhibition, cell death, structural components, cell signaling and inflammation. Gene expression profile was further correlated with biochemical analysis and histopathological lesions. These data show that gene expression profiling would help in better understanding the molecular basis of drug-induced hepatotoxicity that will lead to rational development of safer drugs, particularly in pre-clinical stages.


Subject(s)
Acetaminophen/toxicity , Acetanilides/toxicity , Analgesics, Non-Narcotic/toxicity , Gene Expression Profiling , Liver/drug effects , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , L-Lactate Dehydrogenase/blood , Liver/metabolism , Liver/pathology , Mice , Mice, Inbred C57BL , Oligonucleotide Array Sequence Analysis , gamma-Glutamyltransferase/blood
8.
Biotechnol J ; 3(7): 938-47, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18348140

ABSTRACT

Phosphodiesterase 4B (PDE4B) is an important therapeutic target for asthma and chronic obstructive pulmonary disease. To identify PDE4 subtype-specific compounds using high-throughput assays, full-length recombinant PDE4 proteins are needed in bulk quantity. In the present study, full-length human PDE4B2 was expressed in the cellular slime mould Dictyostelium discoideum (Dd). A cell density of 2 x 10(7) cells/mL was obtained and up to 1 mg/L recombinant PDE4B2 was purified through Ni-NTA affinity chromatography. The expressed protein was soluble and its activity was comparable to PDE4B2 protein expressed in mammalian cells (K(m)=1.7 microM). The functional significance of the Dd expression system is supported by the demonstration that, in concert with proteins expressed in mammalian systems, there are no major changes in the affinity for PDE4B2 inhibitors and substrates. These findings thus provide the first evidence that Dd can be utilized for the expression and purification of functionally active full-length human PDE4B2 in large amounts required for high-throughput screening of pharmacologically active compounds against this therapeutic target.


Subject(s)
Cyclic Nucleotide Phosphodiesterases, Type 4/biosynthesis , Dictyostelium/enzymology , Dictyostelium/metabolism , Recombinant Proteins/biosynthesis , Animals , Chromatography, Affinity , Cloning, Molecular , Cyclic Nucleotide Phosphodiesterases, Type 4/isolation & purification , Enzyme Inhibitors/pharmacology , Genetic Vectors , Humans , Kinetics , Phosphodiesterase 4 Inhibitors , Plasmids , Recombinant Proteins/isolation & purification , Substrate Specificity , Transformation, Genetic
9.
Biotechnol Appl Biochem ; 49(Pt 2): 129-34, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17640173

ABSTRACT

The cDNA encoding PDE10A (phosphodiesterase 10A) was cloned and a stable recombinant HEK-293 (human embryonic kidney-293) cell line expressing high levels of PDE10A was generated. Transient transfection of pCRE-Luc plasmid, harbouring the luciferase reporter gene under the control of CRE (cAMP-response element)-binding sequence, into the stable recombinant cell line, followed by treatment with PDE10 inhibitor, resulted in a dose-dependent increase in luciferase activity. This method provides a simple and sensitive cell-based assay for screening of PDE10 inhibitors for development of novel therapeutics for the treatment of neurological disorders.


Subject(s)
Biological Assay/methods , Biosensing Techniques/methods , Kidney/drug effects , Kidney/metabolism , Phosphodiesterase Inhibitors/administration & dosage , Phosphoric Diester Hydrolases/metabolism , Spectrometry, Fluorescence/methods , Cell Line , Humans , Luminescent Measurements/methods , Phosphodiesterase Inhibitors/analysis , Recombinant Proteins/metabolism
10.
Appl Microbiol Biotechnol ; 77(5): 1167-73, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17952431

ABSTRACT

Phosphodiesterases (PDEs) constitute a superfamily of enzymes that plays an important role in signal transduction by catalysing the hydrolysis of cAMP and cGMP. cDNA encoding PDE7A1 subtype was cloned and a stable recombinant HEK 293 cell line expressing high levels of PDE7A1 was generated. Transient transfection of pCRE-Luc plasmid, harboring luciferase reporter gene into the stable recombinant cell line and subsequent treatment with PDE7 inhibitor, resulted in a dose-dependent increase in luciferase activity. This method provides a simple and sensitive cell-based assay for screening of PDE7 selective inhibitors for the treatment of T cell mediated diseases.


Subject(s)
Cyclic Nucleotide Phosphodiesterases, Type 7/antagonists & inhibitors , Cyclic Nucleotide Phosphodiesterases, Type 7/biosynthesis , Phosphodiesterase Inhibitors/pharmacology , Cell Line , Cloning, Molecular , Cyclic Nucleotide Phosphodiesterases, Type 7/genetics , Drug Evaluation, Preclinical/methods , Gene Expression , Genes, Reporter , Humans , Luciferases/genetics , Luciferases/metabolism
11.
Biochem Biophys Res Commun ; 356(1): 153-8, 2007 Apr 27.
Article in English | MEDLINE | ID: mdl-17336928

ABSTRACT

Phosphodiesterase (PDE) constitutes a superfamily of enzymes that catalyze the hydrolysis of cAMP and cGMP into their corresponding monophosphates and play an important role in diverse physiological functions. The present study provides a process for identifying PDE4 subtypes selective inhibitors using a reporter gene assay. Stable recombinant HEK-293 cell lines expressing high levels of PDE4A4B, PDE4B2A, and PDE4D3 subtypes individually were generated. Transient transfection of pCRE-Luc plasmid, harboring luciferase reporter gene under the control of cAMP response element (CRE)-binding sequence, into these stable recombinant cell lines followed by treatment with PDE4 inhibitor, resulted in a dose dependent increase in luciferase activity. This methods provide a novel, simple and sensitive assay for high throughput screening of PDE4 subtype selective inhibitors for treatment of asthma and COPD.


Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , Luciferases/metabolism , Phosphodiesterase Inhibitors/pharmacology , 3',5'-Cyclic-AMP Phosphodiesterases/genetics , 3',5'-Cyclic-AMP Phosphodiesterases/metabolism , Aminopyridines/pharmacology , Benzamides/pharmacology , Cell Line , Cloning, Molecular , Cyclic AMP/metabolism , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic Nucleotide Phosphodiesterases, Type 4 , Cyclopropanes/pharmacology , Cytoplasm/enzymology , Dose-Response Relationship, Drug , Humans , Immunohistochemistry , Isoenzymes/antagonists & inhibitors , Isoenzymes/genetics , Isoenzymes/metabolism , Kinetics , Luciferases/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Regulatory Sequences, Nucleic Acid , Rolipram/pharmacology , Transfection , U937 Cells
12.
Biotechnol Lett ; 28(21): 1731-9, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16912925

ABSTRACT

The cDNAs encoding for three subtypes of adrenergic receptors, alpha1A-, alpha1B- and alpha1D-ARs, were cloned and expressed in HEK 293 cells. Expression of alpha1A- and alpha1B-AR subtypes in HEK 293 cells was stable even with increased passages but that of alpha1D-AR was not. Cellular localization studies using immunofluorescence and flow cytometry revealed that expression of alpha1A- and alpha1B-ARs was primarily localized on the cell membrane whereas expression of alpha1D-AR was predominantly intracellular. Our studies clearly demonstrated that the culturing of the recombinant cell lines expressing alpha1D-AR in charcoal/dextran treated fetal bovine serum (FBS) resulted in targeting of alpha1D-AR to the cell membrane and thus, significantly improving its stability and availability for ligand binding studies.


Subject(s)
Culture Media/chemistry , Culture Media/pharmacology , Gene Expression Regulation/drug effects , Receptors, Adrenergic, alpha-1/metabolism , Recombinant Proteins/metabolism , Cell Culture Techniques , Cell Line , Cell Membrane/metabolism , Cells, Cultured , Charcoal/pharmacology , Cloning, Molecular , DNA, Complementary/isolation & purification , Dextrans/pharmacology , Embryo, Mammalian/cytology , Fetal Blood/chemistry , Flow Cytometry , Humans , Kidney/cytology , Receptors, Adrenergic, alpha-1/genetics , Recombinant Proteins/genetics , Serum/chemistry
13.
Biotechnol Lett ; 28(2): 121-9, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16369696

ABSTRACT

cDNAs encoding for five mAChR subtypes (M1-M5) were cloned under different promoters in various eukaryotic vectors and each subtype was expressed in different mammalian cell lines. CHO-K1 cell line was the best for generating stable cell lines expressing muscarinic receptors. Immunofluorescence and flow cytometry revealed that expression of M1-M5 was primarily localized on the cell membrane. Western blotting and radio-ligand binding studies revealed that expression of each receptor was stable at higher passages.


Subject(s)
Gene Expression , Receptor, Muscarinic M1/biosynthesis , Receptor, Muscarinic M5/biosynthesis , Animals , Blotting, Western , CHO Cells , Cell Membrane/metabolism , Cloning, Molecular , Cricetinae , Cricetulus , Flow Cytometry , Humans , Radioligand Assay , Receptor, Muscarinic M1/genetics , Receptor, Muscarinic M5/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...